



SkinBioTherapeutics plc
("SkinBioTherapeutics" or "the Company")

Directorate Changes

5 January 2026 - SkinBioTherapeutics, (AIM: SBTX), a life science company focused on skin health, announces the appointment of Alyson Levett as new non-executive director and Chair of the Audit Committee and the promotion of Emily Bertram to Chief Financial Officer and also to the Board. Danielle Bekker has stepped down from the Board but will continue to support as an external advisor effective from 31 December 2025. The appointments came into effect from 1 January 2026.

Alyson Levett, Non-Executive Director and Chair of Audit Committee

Alyson Levett is a highly experienced non-executive Director and Chair of Audit & Risk Committees. She has worked in a broad range of sectors including FMCG, food manufacturing, engineering and technology, with proven expertise with AIM companies and a wealth of shareholder and other stakeholder engagement and relationship experience. She has over 20 years C suite financial experience, culminating in being CFO at the strategy software company, i-nexus where she stayed for a decade taking it onto AIM in a successful IPO in 2018. She left to develop a portfolio Non-Executive career, focussing on the role of Chair of the Audit Committee or Audit & Risk Committee. Her current directorships are listed below, but include GETECH Group plc, Eleco plc and the Financial Services Compensation Scheme. She also acts as a Trustee on the charitable trust, En-Fold Autism Support, and is a volunteer advisor at The Cranfield Trust. She read Economics at Cambridge University and is a qualified Chartered accountant (ICAEW).

Emily Bertram, Chief Financial Officer and Executive Officer to the Board

Emily Bertram has been promoted from Group Finance Director to Chief Financial Officer and has become an executive Director on the Board of SkinBioTherapeutics, following the AGM. Emily is an experienced certified Chartered Accountant (ACCA) who has led and worked within finance teams in a variety of industries, from business advisory groups to medical technology and pharma companies, to banking. Before SkinBioTherapeutics, Emily was Group Head of Financial Planning and Analysis at Azets, the international business advisory group. Prior to this, she held senior finance positions at THF Holdings, Leica Biosystems, Quantum Pharma, Northumbria University (Faculty of Health & Life Sciences), Alta Link and Northern Rock. She has a 1st class BA (Hons) in Accounting from Northumbria University.

Martin Hunt, Chairman of SkinBioTherapeutics, said:

"On behalf of the Board, I'm delighted to welcome both Alyson and Emily to the Board, and congratulate Emily on her promotion. I'd also like to thank Cathy Prescott for the work she's done as Chair of the Audit Committee and for Danielle for staying on as an advisor. These appointments strengthen the Board, especially the financial elements and provide welcome support to the Executive Management as we enter a busy 2026."

-Ends-

The following information is disclosed pursuant to rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies:

Full name:	Alyson Levett
Age:	59
Shareholding in	N.i.l

SkinBioTherapeutics:	I VII
Current directorships held:	Eleco plc, NED GETECH Group plc, NED En-Fold Autism Support Northamptonshire, Trustee Financial Services Compensation Scheme, NED AMTE Power, NED (in administration)
Directorships held in the previous 5 years:	i-nexus - NED, resigned December 2022

Full name:	Emily Bertram
Age:	42
Shareholding in SkinBioTherapeutics:	Nil
Current directorships held:	NA
Directorships held in the previous 5 years:	NA

-Ends-

For more information please contact:

SkinBioTherapeutics plc

Stuart J. Ashman, CEO
Emily Bertram, Group Finance Director

+44 (0) 191 495 7325

Singer Capital Markets (Nominated Adviser & Broker)

+44 (0) 020 7496 3000

Philip Davies
Andrew Johnson
James Todd

Vigo Consulting (financial press)

Rozi Morris, Melanie Toyne-Sewell

+44 (0) 20 7390 0230

SkinBio@vigoconsulting.com

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Group's proprietary platform technology, SkinBiotix®, is based upon discoveries made by the translational dermatology team at the University of Manchester. The Group's foundation business is targeting the skin healthcare market via five pillars, the most advanced of which are cosmetic skincare (SkinBiotix®) and food supplements that harness the gut-skin axis (AxisBiotix™). The cosmetic pillar has a partnership with Croda plc where SkinBiotix® is being used as an active skin ingredient with the Croda trade name, Zenakine™. The AxisBiotix™ pillar has a range of products targeting the symptoms of inflammatory skin conditions, being sold directly and via Amazon, and on the High Street in selected Superdrug Stores plc stores.

The Group is also acting as a consolidator and is making acquisitions in complementary areas such as skincare and cosmetic applications, that also bring new distribution and geographical platforms, and manufacturing capabilities through which it can funnel its in-house pillar products.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.skinbiotherapeutics.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BOAKZGGMKDRGVZM